Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results.
Rev Esp Enferm Dig
; 114(2): 118-119, 2022 02.
Article
en En
| MEDLINE
| ID: mdl-34517718
ABSTRACT
A new subcutaneous formulation of the infliximab biosimilar CT-P13 has recently been developed for the treatment of inflammatory bowel disease (IBD), providing response rates similar to intravenous treatment. The use of this new formulation was requested, in an effort to limit patient attendance at intravenous infusion centers and to maintain biological treatment during the COVID-19 pandemic. The objective of this observational, retrospective and descriptive study was to assess CT-P13 efficacy and safety after switching from intravenous to a subcutaneous formulation in patients with IBD receiving maintenance therapy. This article shows preliminary results after six months of follow-up.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Enfermedades Inflamatorias del Intestino
/
Biosimilares Farmacéuticos
/
COVID-19
Tipo de estudio:
Observational_studies
Límite:
Humans
Idioma:
En
Revista:
Rev Esp Enferm Dig
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2022
Tipo del documento:
Article